Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 14/20 | 0.38 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.38 |
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 0.38 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL351288 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| Maleic Acid SCHEMBL353037 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| Fumaric Acid SCHEMBL353035 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| Fumaric Acid SCHEMBL351290 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| Maleic Acid SCHEMBL352365 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| Oxalic Acid SCHEMBL351294 | 0.87 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| Oxalic Acid SCHEMBL352319 | 0.87 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL17137 | 0.85 | — | — | |
| SCHEMBL554471 | 0.85 | — | — | |
| SCHEMBL619548 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648190-B2 | Process for producing 2-hydroxymethylmorpholine salt | DAISO CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| EP-2388252-B1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | DAISO CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2388252-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | Daiso Co., Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-8040010-B2 | Permanent magnet type generator and hybrid vehicle using the same | HITACHI, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016120-A1 | PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT | THOP1, AVPR2, HPD | SLC6A2 77/4885SLC6A3 206/4885SLC6A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.